R C Verdonk
Overview
Explore the profile of R C Verdonk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Biesma N, Graus M, Cirkel G, Besselink M, de Groot J, Koerkamp B, et al.
Eur J Surg Oncol
. 2024 Dec;
51(3):109544.
PMID: 39689462
Introduction: Adjuvant chemotherapy improves survival in patients with resected pancreatic ductal adenocarcinoma (PDAC). The decision to initiate chemotherapy involves both patient and physician factors, decision-specific criteria, and contextual considerations. This...
2.
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials
. 2024 Jul;
25(1):456.
PMID: 38970096
No abstract available.
3.
van Goor I, Andel P, Buijs F, Besselink M, Bonsing B, Bosscha K, et al.
Ann Surg Oncol
. 2024 Jun;
31(12):8264-8275.
PMID: 38937412
Background: Distinguishing postoperative fibrosis from isolated local recurrence (ILR) after resection of pancreatic ductal adenocarcinoma (PDAC) is challenging. A prognostic model that helps to identify patients at risk of ILR...
4.
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials
. 2024 Jun;
25(1):401.
PMID: 38902836
Background: Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most patients experience local and/or distant PDAC recurrence...
5.
de Rijk F, Sissingh N, Boel T, Timmerhuis H, de Jong M, Pauw H, et al.
J Gastroenterol Hepatol
. 2024 Jan;
39(4):674-684.
PMID: 38191176
Background And Aim: More insight into the incidence of and factors associated with progression following a first episode of acute pancreatitis (AP) would offer opportunities for improvements in disease management...
6.
Mackay T, Smits F, Latenstein A, Bogte A, Bonsing B, Bos H, et al.
Trials
. 2020 Apr;
21(1):334.
PMID: 32299515
Background: Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical...
7.
Umans D, Hallensleben N, Verdonk R, Bouwense S, Fockens P, van Santvoort H, et al.
Br J Surg
. 2019 Dec;
107(3):191-199.
PMID: 31875953
Background: Occult biliary disease has been suggested as a frequent underlying cause of idiopathic acute pancreatitis (IAP). Cholecystectomy has been proposed as a strategy to prevent recurrent IAP. The aim...
8.
Smeets X, Bouhouch N, Buxbaum J, Zhang H, Cho J, Verdonk R, et al.
United European Gastroenterol J
. 2019 May;
7(4):557-564.
PMID: 31065373
Background And Objective: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most prevalent complication after ERCP with an incidence of 3.5%. PEP severity is classified according to either the consensus...
9.
HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1
van Gerven N, de Boer Y, Zwiers A, Verwer B, Drenth J, Van Hoek B, et al.
Genes Immun
. 2015 Jan;
16(4):247-52.
PMID: 25611558
The classical human leukocyte antigen (HLA)-DRB1*03:01 and HLA-DRB1*04:01 alleles are established autoimmune hepatitis (AIH) risk alleles. To study the immune-modifying effect of these alleles, we imputed the genotypes from genome-wide...
10.
Mantel H, Verdonk R, Van Dullemen H, Gietema J, Slooff M, Porte R
Ned Tijdschr Geneeskd
. 2008 Jun;
152(18):1037-41.
PMID: 18547024
--Cholangiocarcinoma is a rare malignancy originating from the biliary epithelium. The disease can arise anywhere in the biliary tract: intrahepatic, perihilar or distal. The overall prognosis for cholangiocarcinoma is poor....